Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VSA012 in Healthy Volunteers
NCT06766929Phase 1Active, not recruiting
- Sponsor
- BiSiRNA Therapeutics
- Start
- Jan 2025
- Primary completion
- Aug 2026
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VSA012 in paroxysmal nocturnal hemoglobinuria (PNH) (5 cohorts), sponsored by BiSiRNA Therapeutics. Primary endpoint: Adverse Events at 180 days. Started Jan 2025; status: active, not recruiting.
02
Drugs
VSA012
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT06766929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06766929.